Please login to the form below

Not currently logged in
Email:
Password:

AMNOG – One Year On...

A review of the impact of new pricing and reimbursement arrangements in Germany

Once the first country in Europe to get innovative products thanks to its favourable pricing structure, Germany was a popular launch destination. But the introduction of AMNOG and the G-BA test has left many wondering if they would not be better off avoiding the country altogether Justus Dehnen, Head of Pricing & Reimbursement, IMS Consulting Group and Olaf Zweig, Principal, Booz & Co review the first year of the new arrangements in detail and provide their insights on the likely impact on pharma companies.


The expert panel includes

  • Justus Dehnen, Pricing and Market Access Leader, Germany
  • Olaf Zweig, Principal, Global Health Practice, Berlin

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...